NR4A1 and neoplasm: They found that a new antineoplastic compound called 2-imino-6-methoxy-2H-chromone-3-carbothioamide (IMCA), which targets the MTC NR4A1 (orphan nuclear receptor 4A1), triggered tumor cell death in a dose-dependent manner.